Sven Moosmang

Company: Boehringer Ingelheim

Job title: Therapeutic Area Head Translational Medicine & Clinical Pharmacology Cardiometabolism

Seminars:

Panel Discussion: How can we Modernize Surrogate Endpoint Development? Moving Beyond Hard Endpoints 8:00 am

Evaluating novel surrogate endpoints in addition to emerging standard of care Non-invasive imaging, patient-reported outcomes, UACR, and more: what is an acceptable endpoint? Considering payers perspectives’ on moving beyond hard endpoints and ESRDRead more

day: Day One